Company Description

Immunicom, a healthcare technology company, seeks to leverage its therapeutic oncology product to address unmet medical needs and improve patient access and affordability of cancer and other inflammatory and autoimmune disease treatments around the world. Immunicom's revolutionary blood-filtering technology has the potential to effectively treat a wide variety of cancer types including those that have not responded to other treatment strategies such as other drug and biological-based immunotherapy options with possibly fewer side effects.

How Does Immunicom’s Technology Work and How Does it Compare to Other Current Technologies in Oncology?

Immunicom has developed a breakthrough approach to cancer immunotherapy that is applicable to all solid tumor cancers.  Immunicom targets soluble immune factors that are secreted by tumor cells that block the immune system from attacking the tumor.  We design proprietary capture molecules that bind exclusively to these “blocking” proteins.  Instead of converting our capture molecule into a drug, we bind it to our proprietary liquid filter, which then attaches to any existing plasmapheresis machine in the hospital.  These machines are similar to dialysis machines and are in every hospital around the world.  The patient gets a couple of IVs attached to them and comfortably sits for a couple of hours while their blood gets filtered through our technology.  Our filter selectively targets only the “blocking” protein produced by the tumor cells and efficiently and safely removes these from the patient’s blood.  Nothing is added to the patient’s body nor any changes made to the patient’s blood chemistry.

Once the “blocking” protein is removed, the tumor is exposed to the immune systems natural cell death processes.  This unique approach has proven to be very safe in over 700 treatments, with patients having almost no side effects and usually improvement in their quality of life.  Because of the potential benefits Immunicom’s approach provides cancer patients, the FDA has granted us Breakthrough Technology Designation.  We have recently gotten our CE Mark regulatory approval in Europe based on compelling early data in our clinical trial.  CE Mark approval is comparable to the FDA and is accepted globally in all countries except the US.

By safely and efficiently removing the “blocking” protein outside the body, we stabilize the immune system and improve the response of other cancer therapies.  While our therapy has been shown to be effective as a stand-alone monotherapy, it also serves as the perfect adjunct therapy for most other cancer therapies, including the latest immunotherapy drugs.  Our goal is to position Immunicom as the perfect therapy to include in any “standard of care” treatment, regardless of which other oncology drug it is being combined.

Our unique approach allows our technology to be approved as a medical device from a regulatory perspective.  This provides for a much faster time to market and easier regulatory approval pathway.  At the same time, our product is an immunotherapy platform for oncology and other major diseases and has market economics and return on investments metrics similar to oncology pharmaceutical products, without the high investment and long time to market issues and risks.  Due to significantly lower development cost, Immunicom’s immunotherapy solutions are expected to be priced closer to current affordable chemotherapy treatments, well below the current immunotherapy drugs the cost anywhere from $120,000 to $250,000 per patient.

Our approach is to make our therapy a “no-brainer” for the oncologist, patient, and payer by making it safe, effective and the perfect combination while improving the patient’s quality of life in an affordable manner.

What is Immunicom’s “Go-to-Market” Strategy and Timelines for Investor Returns?

Immunicom is in a unique position to be able to leverage rapid global regulatory approval in oncology due to its European CE Mark approval and FDA Breakthrough Technology Designation.  We have trials underway in Europe for Triple Negative Breast Cancer, Tel Aviv Israel for Melanoma, and Istanbul for Lung Cancer.  Our technology platform allows us to rapidly develop products for other diseases, like Cardiovascular and Auto-Immune conditions.  We expect to have 2 additional products developed by Q3 2020.  These products have applicability to the aforementioned disease conditions but also for treatment of critically ill COVID-19 patients.

Our expectation is to potentially have multiple major monetization events for our shareholders beginning in 2022.

Business Model and Advantages

The broad multiple major market segment applicability of our platform, combined with the ability of our solution to work seamlessly with existing drugs and protocols, should make Immunicom a very attractive target. Our strategy is to partner with major regional pharmaceutical companies around the world to bring our product to market either through lucrative and large licensing arrangements or technology acquisition.  In the therapeutic oncology sector, these deals range anywhere from $500M+ to multi-billion.

By the end of this year, we expect to have compelling data across multiple cancers, further European and potential FDA approvals being executed, and other major disease treatments with associated intellectual property.  This should allow us to be positioned for discussions and negotiations during 2021 with the aforementioned pharmaceutical companies.

What are the Key Risk Factors and How Has the Company Mitigated These Risks

There are 3 common risk factors for biotech companies at Immunicom’s stage: 1) clinical trial design and outcome, 2) execution and management team, 3) adequate capital.  We believe we have properly mitigated all 3 of these risk factors.

1)      Clinical trial design and outcome:  Most companies at Immunicom’s size and stage have one clinical trial that determines the company’s future outcome.  The risks are significant as many factors can lead to failure of a trial and the subsequent demise of the company.  Fortunately, Immunicom’s technology was compelling enough to get 2 major strategic partners to fund additional trials for multiple cancer indications.

Immunicom has 3 concurrent trials, all slated to be completed by mid to late 2021.  Our primary trial is being conducted in Europe focusing on Triple Negative Breast Cancer (TNBC) and is directly funded by Immunicom.  Our Melanoma trial at Sheba Medical Center in Tel Aviv is being funded by Henry Samueli, co-founder of Broadcom and tech billionaire.  Our Lung Cancer trial is 75% funded by Acibadem Hospital and Medical University System, the second largest private healthcare system in Asia with premier Tier 1 hospitals.

We already have compelling enough data from our TNBC European trial to obtain early European CE Mark approval.  We anticipate positive results from our Israeli and Turkish trials.  By spreading the risk across 3 trials and multiple cancers, without incurring the financial burden of all 3 trials, we believe we have significantly mitigated our risk.  One successful trial in oncology creates enormous value potentially worth billions of dollars.

2)      Execution and management team:  Immunicom has successfully executed against its key milestones in the past.  Our management team is experienced and seasoned in both running multibillion-dollar global operations as well as successful startup companies.  We have over 200 years of combined experience as seasoned healthcare technology executives with over $13B created in shareholder value, 10+ successful major mergers and acquisitions (M&A) transactions, more the 50 healthcare technology products commercialized globally, and 3 successful IPOs.  During the current global pandemic crisis, we were able to keep our key clinical trials on track, successfully secure our European approval, expand our manufacturing capabilities, while extending our fiscal run rate without requiring assistance from our existing shareholders.  Every management team in the world is being tested right now.  We have demonstrated that not only can we execute during a global crisis, but also keep the company moving forward at a rapid pace.  As they say in Texas, where our CEO / founder (Amir Jafri) is from, “this isn’t our first rodeo."  We have successfully built, run, and exited companies many times in our career.

3)      Adequate capital:  Immunicom has raised $25M to-date across 2 rounds from high net-worth individuals and family offices.  Our Series B round had a post-money valuation of $84M.  We expect our Series C round to potentially be our final capital round, providing adequate capital to achieve a monetization event that not only makes the company financially secure, but potentially provides our shareholders with a return on investment (see Question 2 answer).  Our financial risk is further mitigated by funding of 2 of our clinical trials through major strategic partners (Henry Samueli / Sheba Medical Center and Acibadem).  We believe we are close to the finish line given the vast majority of our funding risk being mitigated through product validation, regulatory approvals, and strategic partnerships.

The Investment Opportunity

$10M Bridge convertible to $30M Series C with escalating valuation cap.

Funds by June 12 – valuation cap $100M with 5% warrant coverage

Funds by July 31 – valuation cap $120M

Projected Series C pre-money valuation $150M (Q4’20 - Q1’21) 

We believe the convertible Bridge funds ($10M) provide adequate runway to secure significant progress through Q2 2021. This allows us to begin our Preferred Series C raise in Q4 2020 at a substantial pre-money valuation, giving the Bridge investor a significant discount on their conversion terms.

Experienced and Focused Team

During their careers, the current Immunicom team has raised over $13B in shareholder value, led 3 successful IPOs, conducted over 10 successful M&A transactions, and successfully commercialized over 50 medical products around the world.          

CEO, President (Founder), Amir Jafri 25 years healthcare technology experience as founder of startups and in senior leadership executive positions in Fortune 50 medical technology companies (Cardinal Health, Manpower Group). Responsible for global product groups with over $1B in annual revenue. Significant experience with FDA and EU regulatory agencies. Founded 2 healthcare technology companies both successfully acquired.

Chairman of the Board, David Schlotterbeck 45 years of experience in healthcare and technology. David has been Chairman and CEO of 3 public (NYSE) and 2 private companies; Vice Chairman of a Fortune 20 company, Cardinal Health (NYSE: CAH). He has created over $11B in shareholder value by dominating medical technology industry segments he entered.

Chief Medical Officer, Dr. Robert Segal, M.D. 25 years of medical and pharmaceutical experience in senior executive positions in Fortune 20 companies (Merck) and biotech startups. Part of senior executive team that successfully executed $750M IPO for life science company. Significant experience with FDA and EU regulatory agencies.

Chief Commercial Officer, Stephen Prince 30 years healthcare technology leadership with over a dozen issued US & international patents. Co- founder of start-up CRISI Medical Systems – acquired by BD in 2015. Prior executive roles in Sales/Marketing/Innovation/Strategy at BD, Cardinal Health, CareFusion, and Gen-Probe. Significant experience in global market development for new FDA-regulated technology products.

While COVID-19 is top of mind across the world and we are developing a version of technology to address oncology and COVID-19, we need to understand the magnitude of the cancer market Immunicom is addressing. As an example, the state of California currently has approximately 3,200 deaths attributed to COVID-19, while it has 60,000 deaths every year related to Stage 4 cancers, a disease condition for which we do not have adequate treatments and one that destroys families emotionally and financially. COVID-19 will ultimately dissipate into a manageable disease, while cancer will continue to ravage patients and their families for decades to come.